ZT-01
Phase 2Small molecule
ZT-01 is one of 55 small molecule programs targeting Type 1 Diabetes. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
384 competitors in Type 1 Diabetes
#DrugCompanyPhaseTrials
1Symlin
AstraZenecaPreclinical
Aldomet
Neurocrine BiosciencesPreclinical
ZT-01
ZZucara Therapeutics Inc.
Phase 2
Pitocin
RRetrophin
Preclinical
Glargine
Eli LillyPreclinical
Cytoxan
BBaxter Healthcare Corporation
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Foradil
ViatrisPreclinical
SGLT2 Inhibitor
Eli LillyPreclinical
Teplizumab
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ZT-01. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- ZZucara Therapeutics Inc.